296 related articles for article (PubMed ID: 35843594)
41. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
[TBL] [Abstract][Full Text] [Related]
42. Paraptosis Inducer to Effectively Trigger Immunogenic Cell Death for Metastatic Tumor Immunotherapy with IDO Inhibition.
Zheng RR; Zhao LP; Huang CY; Cheng H; Yang N; Chen ZX; Cai H; Zhang W; Kong RJ; Li SY
ACS Nano; 2023 Jun; 17(11):9972-9986. PubMed ID: 37200049
[TBL] [Abstract][Full Text] [Related]
43. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
44. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
45. A novel prodrug and its nanoformulation suppress cancer stem cells by inducing immunogenic cell death and inhibiting indoleamine 2, 3-dioxygenase.
Guan J; Wu Y; Liu X; Wang H; Ye N; Li Z; Xiao C; Zhang Z; Li Z; Yang X
Biomaterials; 2021 Dec; 279():121180. PubMed ID: 34768152
[TBL] [Abstract][Full Text] [Related]
46. Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.
Liu Q; Chen F; Hou L; Shen L; Zhang X; Wang D; Huang L
ACS Nano; 2018 Aug; 12(8):7812-7825. PubMed ID: 30016071
[TBL] [Abstract][Full Text] [Related]
47. Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer.
Zhang W; Gong C; Chen Z; Li M; Li Y; Gao J
J Nanobiotechnology; 2021 Oct; 19(1):339. PubMed ID: 34689761
[TBL] [Abstract][Full Text] [Related]
48. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
[TBL] [Abstract][Full Text] [Related]
49. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract][Full Text] [Related]
50. Semiconducting Polymer Nanoparticles with Surface-Mimicking Protein Secondary Structure as Lysosome-Targeting Chimaeras for Self-Synergistic Cancer Immunotherapy.
Qi J; Jia S; Kang X; Wu X; Hong Y; Shan K; Kong X; Wang Z; Ding D
Adv Mater; 2022 Aug; 34(31):e2203309. PubMed ID: 35704513
[TBL] [Abstract][Full Text] [Related]
51. Mitochondria-targeted polyprodrug nanoparticles induce mitochondrial stress for immunogenic chemo-photodynamic therapy of ovarian cancer.
Zhang W; Chen G; Chen Z; Yang X; Zhang B; Wang S; Li Z; Yang Y; Wu Y; Liu Z; Yu Z
J Control Release; 2024 Jul; 371():470-483. PubMed ID: 38849094
[TBL] [Abstract][Full Text] [Related]
52. Sequential receptor-mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment.
Shen J; Sun C; Wang Z; Chu Z; Liu C; Xu X; Xia M; Zhao M; Wang C
Int J Pharm; 2021 May; 601():120553. PubMed ID: 33794325
[TBL] [Abstract][Full Text] [Related]
53. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
Qi J; Jin F; Xu X; Du Y
Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
[TBL] [Abstract][Full Text] [Related]
54. Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy.
Georganaki M; Ramachandran M; Tuit S; Núñez NG; Karampatzakis A; Fotaki G; van Hooren L; Huang H; Lugano R; Ulas T; Kaunisto A; Holland EC; Ellmark P; Mangsbo SM; Schultze J; Essand M; Tugues S; Dimberg A
Oncoimmunology; 2020; 9(1):1730538. PubMed ID: 32231867
[TBL] [Abstract][Full Text] [Related]
55. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
56. Hybrid micelles codelivering shikonin and IDO-1 siRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment.
Li J; Zhao M; Xu Y; Hu X; Dai Y; Wang D
Int J Pharm; 2021 Mar; 597():120310. PubMed ID: 33540035
[TBL] [Abstract][Full Text] [Related]
57. Host cell depletion of tryptophan by IFNγ-induced Indoleamine 2,3-dioxygenase 1 (IDO1) inhibits lysosomal replication of Coxiella burnetii.
Ganesan S; Roy CR
PLoS Pathog; 2019 Aug; 15(8):e1007955. PubMed ID: 31461509
[TBL] [Abstract][Full Text] [Related]
58. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
59. Delivery of small interfering RNA against Nogo-B receptor via tumor-acidity responsive nanoparticles for tumor vessel normalization and metastasis suppression.
Wang B; Ding Y; Zhao X; Han X; Yang N; Zhang Y; Zhao Y; Zhao X; Taleb M; Miao QR; Nie G
Biomaterials; 2018 Aug; 175():110-122. PubMed ID: 29803999
[TBL] [Abstract][Full Text] [Related]
60. A polymeric IDO inhibitor based on poly(ethylene glycol)-
Liu Y; Xie J; Zhao X; Zhang Y; Zhong Z; Deng C
Biomater Sci; 2022 Sep; 10(19):5731-5743. PubMed ID: 36039890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
